TY - JOUR
T1 - 17β-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma
T2 - A correlation to clinicopathological parameters
AU - Suzuki, T.
AU - Moriya, T.
AU - Ariga, N.
AU - Kaneko, C.
AU - Kanazawa, M.
AU - Sasano, H.
N1 - Funding Information:
This work was supported by a grant-in-aid-for Cancer Research 7–1 from the Ministry of Health and Welfare, Japan, a grant-in-aid -for scientific research area on priority area (A-11137301) from the Ministry of Education, Science and Culture, Japan, a grant-in-aid -for Scientific Research (B-11470047) from the Japan Society for the Promotion of Science, and a grant from The Naitou Foundation and Suzuken Memorial Foundation. We thank Mr. Andrew Darnel, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan, for editing this manuscript.
PY - 2000
Y1 - 2000
N2 - The expression of 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 and type 2 was examined immunohistochemically in 111 invasive ductal carcinomas, and correlated with various clinicopathological parameters. This study investigates local regulatory mechanisms of oestrogens in human breast carcinoma. 17β-HSD type 1 was immunolocalized in carcinoma cells of 68 out of 111 invasive ductal carcinoma cases (61.3%). 17β-HSD type 2 immunoreactivity was not detected in all cases examined. A significant inverse correlation was observed between the immunohistochemical expression of 17β-HSD type 1 and histological grade of the carcinoma (P < 0.02). There was a significant correlation between 17β-HSD type 1 and oestrogen receptor (ER) labelling index (LI) (P < 0.05). In addition, carcinoma cells expressing immunoreactive 17β-HSD type 1 were frequently positive for ER. 17β-HSD type 1 was also correlated with progesterone receptor (PR) LI (P < 0.05). There was a significant inverse correlation between 17β-HSD type 1 and Ki-67 LI (P < 0.0001). No significant correlations were detected between 17β-HSD type 1 and other clinicopathological parameters, including patient age, menopausal status, stage, tumour size, lymph node status and prognosis. This study suggests that 17β-HSD type 1 plays an important role in the regulation of in situ oestradiol production in hormone-dependent breast carcinomas. (C) 2000 Cancer Research Campaign.
AB - The expression of 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 and type 2 was examined immunohistochemically in 111 invasive ductal carcinomas, and correlated with various clinicopathological parameters. This study investigates local regulatory mechanisms of oestrogens in human breast carcinoma. 17β-HSD type 1 was immunolocalized in carcinoma cells of 68 out of 111 invasive ductal carcinoma cases (61.3%). 17β-HSD type 2 immunoreactivity was not detected in all cases examined. A significant inverse correlation was observed between the immunohistochemical expression of 17β-HSD type 1 and histological grade of the carcinoma (P < 0.02). There was a significant correlation between 17β-HSD type 1 and oestrogen receptor (ER) labelling index (LI) (P < 0.05). In addition, carcinoma cells expressing immunoreactive 17β-HSD type 1 were frequently positive for ER. 17β-HSD type 1 was also correlated with progesterone receptor (PR) LI (P < 0.05). There was a significant inverse correlation between 17β-HSD type 1 and Ki-67 LI (P < 0.0001). No significant correlations were detected between 17β-HSD type 1 and other clinicopathological parameters, including patient age, menopausal status, stage, tumour size, lymph node status and prognosis. This study suggests that 17β-HSD type 1 plays an important role in the regulation of in situ oestradiol production in hormone-dependent breast carcinomas. (C) 2000 Cancer Research Campaign.
KW - 17β-HSD
KW - Breast
KW - Carcinoma
KW - Human
KW - Immunohistochemistry
KW - Oestrogen
UR - http://www.scopus.com/inward/record.url?scp=0034132569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034132569&partnerID=8YFLogxK
U2 - 10.1054/bjoc.1999.0956
DO - 10.1054/bjoc.1999.0956
M3 - Article
C2 - 10682658
AN - SCOPUS:0034132569
SN - 0007-0920
VL - 82
SP - 518
EP - 523
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 3
ER -
